Under the following link, you will find the corresponding media release
The transaction will create two leading companies: Merck & Co. Inc. (hereinafter jointly referred to with the Company’s subsidiaries as “MSD”) and Organon & Co (hereinafter jointly referred to with the Company’s subsidiaries as “Organon”).
The transaction (hereinafter referred to as the “Spin-off”) is expected to be completed during the first half of 2021. We believe that the planned spin-off will put both companies in a position to better respond to the specific needs of their patients and customers. You can find further information on our microsite
In connection with the spin-off, certain parts of MSD’s business, including certain products and the related marketing authorizations, will be transferred from MSD to Organon in due course.
Since November 1, 2020, the transferred part of the business in Switzerland has been carried out by the new company Organon GmbH. It will remain a subsidiary of MSD until the global transaction is completed in the first half of 2021.